Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.43 |
| ▸ | NRAS | P01111 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | KIT | P10721 | 4/20 | 0.39 |
| ▸ | CSF1R | P07333 | 3/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239508 | 0.96 | FLT3 (0.58) | FLT3IRAK4NRASKDRKIT | |
| SCHEMBL10238522 | 0.87 | FLT3 (0.43) | FLT3IRAK4NRASKDR | |
| SCHEMBL24975663 | 0.87 | FLT3 (0.62) | FLT3IRAK4NRASKDRKIT | |
| SCHEMBL27362520 | 0.84 | FLT3 (0.57) | FLT3IRAK4NRASKDRKIT | |
| SCHEMBL24977141 | 0.84 | FLT3 (0.57) | FLT3IRAK4NRASKDRKIT | |
| SCHEMBL12553680 | 0.84 | FLT3 (0.42) | FLT3IRAK4NRASIRAK1 | |
| SCHEMBL10238516 | 0.83 | FLT3 (0.61) | FLT3IRAK4NRASKDRKIT | |
| SCHEMBL10239098 | 0.83 | IRAK4 (0.56) | FLT3IRAK4 | |
| SCHEMBL10239837 | 0.83 | FLT3 (0.55) | FLT3IRAK4NRASKDRKIT | |
| SCHEMBL376585 | 0.83 | FLT3 (0.68) | FLT3IRAK4NRASKDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | FLT3 496/4885IRAK4 816/4885NRAS 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.